GO:0018344 protein geranylgeranylation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0018344 protein geranylgeranylation is the covalent attachment of a 20-carbon geranylgeranyl isoprenoid group to a protein, typically on a C-terminal cysteine.
• It is a branch of the mevalonate pathway and is catalyzed mainly by geranylgeranyltransferases GGTase-I and GGTase-II (RABGGTA/RABGGTB), with farnesyltransferase (FNTA/FNTB) also able to geranylgeranylate some substrates.
• The process controls membrane anchoring and function of small GTPases such as RHOA, RAC1, CDC42, RAB and RAP proteins, thereby regulating cytoskeleton, vesicle traffic, proliferation and immune cell migration.
• The balance between farnesylation and geranylgeranylation is critical in metabolic and cardiovascular disease, including nonalcoholic fatty liver disease and congenital heart defects.
• Statins and prenyltransferase inhibitors alter geranylgeranylation, making this pathway a major pharmacological and experimental target.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to dissect which prenyltransferase and substrate pairs drive specific phenotypes.
Description
Protein geranylgeranylation (GO:0018344) is a post-translational lipid modification in which a geranylgeranyl group is covalently attached to a target protein. This modification increases protein hydrophobicity and promotes association with cellular membranes, which is essential for the biological activity of many small GTPases and other regulatory proteins. Because geranylgeranylation depends on intermediates of the mevalonate pathway, it sits at the intersection of lipid metabolism, signal transduction and cell fate control. Researchers study this process to understand how cells organize membrane signaling, how immune cells migrate, and how metabolic or cardiovascular disease arises when prenylation balance is disturbed. The reaction is catalyzed by dedicated prenyltransferases, and its substrate specificity, regulation and disease relevance are active areas of investigation.
protein geranylgeranylation At A Glance
| GO ID | GO:0018344 |
|---|---|
| GO term | protein geranylgeranylation |
| Ontology | biological_process |
| Synonym | C-terminal protein geranylgeranylation; protein amino acid geranylgeranylation |
| Definition | The covalent attachment of a geranylgeranyl group to a protein. |
| Major function | Membrane anchoring and functional activation of small GTPases and other proteins |
| Key enzymes | GGTase-I (FNTA/FNTB), GGTase-II/RAB GGTase (RABGGTA/RABGGTB), and in some contexts farnesyltransferase (FNTA/FNTB) |
| Substrate motif | Typically C-terminal CaaX or related cysteine-containing sequences |
| Lipid donor | Geranylgeranyl diphosphate (GGPP), a mevalonate pathway intermediate |
What Is GO:0018344?
According to the Gene Ontology, GO:0018344 protein geranylgeranylation is the biological process defined as the covalent attachment of a geranylgeranyl group to a protein. In practice, this means a 20-carbon geranylgeranyl lipid is transferred from geranylgeranyl diphosphate (GGPP) to a cysteine residue, usually within a C-terminal CaaX motif or related sequence, forming a thioether bond that anchors the protein to membranes. The term is synonymous with C-terminal protein geranylgeranylation and protein amino acid geranylgeranylation. It is distinct from, but mechanistically related to, protein farnesylation, and the two modifications are often studied together as protein prenylation.
Why Is protein geranylgeranylation Important in Cell Biology?
Protein geranylgeranylation is important because it determines whether many signaling proteins can localize to membranes and function properly. Small GTPases such as RHOA, RAC1, CDC42 and RAB proteins require geranylgeranylation for membrane association, and loss of this modification disrupts cytoskeletal dynamics, vesicle trafficking, cell proliferation and immune cell egress. Because the mevalonate pathway supplies the geranylgeranyl donor, this process links cholesterol synthesis, statin pharmacology and metabolic disease. In addition, an imbalance between farnesylation and geranylgeranylation has been implicated in nonalcoholic fatty liver disease and congenital heart defects, making the pathway clinically relevant beyond basic cell biology.
• Controls membrane targeting and activity of Rho, Rac, Cdc42, Rab and Rap small GTPases.
• Regulates thymocyte egress and immune cell migration through mevalonate-dependent geranylgeranylation.
• Is a key branch of the mevalonate pathway and is therefore affected by statins and prenyltransferase inhibitors.
• The balance between farnesylation and geranylgeranylation influences nonalcoholic fatty liver disease progression.
• Altered geranylgeranylation has been proposed as a contributor to congenital heart defects.
• Provides a mechanism for intracellular lipid surveillance and metabolic signaling.
• Is a target for anticancer and anti-inflammatory strategies aimed at prenyltransferases.
• Requires careful experimental dissection using knockout, point-mutation and knock-in models.
What Happens During protein geranylgeranylation?
Recognition of the substrate CaaX motif
In simple terms: The enzyme first recognizes a short tag at the end of the target protein.
Most geranylgeranylated proteins carry a C-terminal CaaX motif or a related cysteine-containing sequence that is recognized by the prenyltransferase. The cysteine within this motif is the site of lipid attachment, and the surrounding residues help determine whether the protein is farnesylated or geranylgeranylated. Structural and biochemical studies have shown that farnesyltransferase can also catalyze geranylgeranylation of shortened target sequences, indicating that substrate recognition is more flexible than once thought.
Transfer of the geranylgeranyl group from GGPP
In simple terms: A 20-carbon lipid is transferred from a donor molecule onto the protein.
The geranylgeranyl group is donated by geranylgeranyl diphosphate (GGPP), an intermediate of the mevalonate pathway. The prenyltransferase catalyzes the formation of a thioether bond between the geranylgeranyl moiety and the cysteine thiol of the substrate. This reaction is energetically driven by the cleavage of the diphosphate group and results in a covalently modified protein.
Membrane anchoring and protein function
In simple terms: The added lipid acts like a sticky anchor that pulls the protein to cell membranes.
Once geranylgeranylated, the protein becomes more hydrophobic and associates with intracellular membranes, which is required for its signaling function. For small GTPases such as Rho, Rac, Cdc42 and Rab proteins, this membrane localization is essential for downstream effects on cytoskeleton, vesicle trafficking and cell growth. Loss of geranylgeranylation prevents proper membrane targeting and can disrupt processes such as thymocyte egress.
Balance with farnesylation and metabolic input
In simple terms: The cell must balance two similar lipid tags, and the choice depends on metabolic supply.
Protein geranylgeranylation competes with protein farnesylation for shared substrates and prenyltransferase components. The relative availability of farnesyl diphosphate and GGPP, which are both mevalonate-derived, influences which modification occurs. This balance is physiologically important, as an altered farnesylation-to-geranylgeranylation ratio has been linked to nonalcoholic fatty liver disease progression.
Regulation by statins and prenyltransferase inhibitors
In simple terms: Drugs that block the mevalonate pathway can reduce geranylgeranylation.
Statins lower mevalonate pathway flux and can indirectly reduce geranylgeranylation of target proteins. Prenyltransferase inhibitors directly block the enzymes that attach geranylgeranyl groups, providing tools to test the contribution of this modification to specific phenotypes. Studies in Th1 cells have used statins and farnesyltransferase inhibition to uncover novel prenylation sites and functional consequences.
Key Genes Involved in GO:0018344 protein geranylgeranylation
The following genes encode the enzymes, donor-pathway components and major substrate proteins that define protein geranylgeranylation research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FNTA | Alpha subunit shared by farnesyltransferase and GGTase-I | Essential for prenyltransferase activity and inhibitor studies |
| FNTB | Beta subunit of farnesyltransferase | Can catalyze geranylgeranylation of some substrates |
| RABGGTA | Alpha subunit of Rab geranylgeranyltransferase (GGTase-II) | Required for geranylgeranylation of Rab GTPases |
| RABGGTB | Beta subunit of Rab geranylgeranyltransferase | Catalytic core for Rab protein geranylgeranylation |
| RHOa | Small GTPase substrate | Membrane anchoring and cytoskeletal signaling |
| RAC1 | Small GTPase substrate | Regulates cytoskeleton and immune cell function |
| CDC42 | Small GTPase substrate | Controls polarity and migration |
| RAB proteins | Family of small GTPases | Vesicle trafficking dependent on geranylgeranylation |
| RAP1A | Small GTPase substrate | Adhesion and signaling |
| HMGCR | Rate-limiting enzyme of mevalonate pathway | Determines GGPP supply and statin response |
| GGPS1 | Geranylgeranyl diphosphate synthase | Produces the geranylgeranyl donor |
| FDPS | Farnesyl diphosphate synthase | Supplies intermediates for both farnesylation and geranylgeranylation |
| PGGT1B | Beta subunit of GGTase-I | Catalyzes geranylgeranylation of Rho-family proteins |
| CHM | Rab escort protein | Presents Rab substrates to GGTase-II |
| RABGGTase accessory proteins | Substrate presentation | Required for Rab geranylgeranylation |
| SREBF2 | Transcriptional regulator of cholesterol synthesis | Links lipid homeostasis to prenylation capacity |
| NR1H2 | Lipid-sensing nuclear receptor | Intracellular lipid surveillance connected to geranylgeranylation |
How Is protein geranylgeranylation Regulated?
Protein geranylgeranylation is regulated at multiple levels. The supply of GGPP depends on mevalonate pathway flux, which is controlled by HMGCR and downstream enzymes and is sensitive to statins. Prenyltransferase expression and subunit availability also influence activity, and the relative abundance of farnesyl diphosphate versus GGPP can shift the balance between farnesylation and geranylgeranylation. In immune cells, mevalonate metabolism-dependent geranylgeranylation regulates thymocyte egress, showing that physiological state and metabolic cues modulate this process. Recent work has also revealed intracellular lipid surveillance mechanisms that respond to geranylgeranylation status. Together, these layers of regulation make geranylgeranylation a dynamic and context-dependent modification.
protein geranylgeranylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HMGCR | Nonalcoholic fatty liver disease and metabolic imbalance | Knockout or point-mutation cell models to alter mevalonate flux |
| RABGGTA | Immune cell egress and trafficking defects | Knockout T-cell models to test thymocyte egress |
| RHOa | Cytoskeletal and cardiovascular signaling | Point-mutation knock-in to prevent geranylgeranylation |
| RAC1 | Inflammation and proliferation | Overexpression and knockout models in immune cells |
| GGPS1 | Congenital heart defects and lipid supply | Knockout or knockdown models to reduce GGPP |
Metabolic and liver disease
The balance between protein farnesylation and geranylgeranylation is disturbed during the progression of nonalcoholic fatty liver disease, suggesting that altered prenylation contributes to hepatic lipid accumulation and injury. Because both modifications draw on mevalonate pathway intermediates, changes in lipid metabolism can shift the ratio and affect downstream small GTPase signaling.
Cardiovascular and congenital heart defects
Protein geranylgeranylation has been proposed as a possible new player in congenital heart defects, linking prenylation-dependent signaling to cardiac development. This connection highlights the importance of precise regulation of geranylgeranylation during embryogenesis.
Immune cell trafficking and inflammation
Mevalonate metabolism-dependent protein geranylgeranylation regulates thymocyte egress, indicating that this modification controls immune cell migration and egress from the thymus. In Th1 cells, statins and farnesyltransferase inhibition alter prenylation patterns, with implications for inflammatory responses.
Cancer and proliferation
Many geranylgeranylated small GTPases promote proliferation, survival and migration, making prenyltransferases attractive targets in cancer research. Inhibitors of geranylgeranylation are studied for their ability to block oncogenic signaling, although the balance with farnesylation complicates therapeutic strategies.
From protein geranylgeranylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GGTase-I block RhoA membrane targeting? | RABGGTA or PGGT1B knockout cells |
| Does a specific cysteine mutation prevent geranylgeranylation? | Point-mutation knock-in of the CaaX cysteine |
| Can a tagged substrate report geranylgeranylation in live cells? | Tagged knock-in of the target protein |
| Does overexpression of a small GTPase alter migration? | Overexpression cell model |
| Which genes buffer loss of geranylgeranylation? | CRISPR library screening |
| Does statin treatment phenocopy prenyltransferase loss? | Pharmacological and knockout comparison |
How to Study the protein geranylgeranylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro prenylation assay | Enzymatic transfer of geranylgeranyl group | Testing GGTase activity and inhibitors |
| Mass spectrometry proteomics | Prenylated peptides and modification sites | Mapping the geranylgeranylated proteome |
| Fluorescence microscopy | Membrane localization of tagged proteins | Assessing functional consequences of geranylgeranylation |
| Western blotting with prenylation-sensitive antibodies | Prenylation status of specific proteins | Validating knockout or inhibitor effects |
| CRISPR knockout | Loss-of-function of prenyltransferase genes | Determining requirement for geranylgeranylation |
| Point-mutation knock-in | Effect of blocking the modification site | Testing substrate-specific geranylgeranylation |
| Overexpression | Gain-of-function of substrate or enzyme | Testing sufficiency in signaling |
| CRISPR library screening | Genome-wide modifiers of geranylgeranylation phenotypes | Identifying buffering pathways |
Biochemical prenylation assays
In vitro prenylation assays using recombinant prenyltransferases and substrate peptides can directly measure geranylgeranylation activity and distinguish it from farnesylation. These assays are useful for testing inhibitors and mutant enzymes.
Proteomics and lipid modification detection
Mass spectrometry-based proteomics can identify prenylated proteins and map modification sites, as shown by studies uncovering novel prenylation sites in Th1 cells. Such approaches help define the geranylgeranylated proteome and its changes under disease conditions.
Imaging and membrane localization
Fluorescence imaging of tagged small GTPases can assess whether geranylgeranylation-dependent membrane targeting occurs. Loss of membrane localization after mutation or inhibitor treatment provides functional evidence for geranylgeranylation.
Genetic and pharmacological perturbation
Knockout of prenyltransferase subunits, point mutation of substrate cysteines, and treatment with statins or prenyltransferase inhibitors are complementary strategies to test the role of geranylgeranylation in cells and animal models.
How CRISPR Can Be Used to Study GO:0018344 protein geranylgeranylation
Knockout
CRISPR knockout of prenyltransferase subunits such as RABGGTA, RABGGTB or PGGT1B can abolish specific branches of geranylgeranylation and reveal which cellular processes depend on them. Knockout of substrate genes can also test whether the geranylgeranylation motif is required for function.
Point Mutation
Point-mutation knock-in of the critical cysteine in a CaaX motif prevents geranylgeranylation without removing the protein, allowing clean separation of lipid modification from protein abundance. This approach is valuable for testing substrate-specific effects.
Knock-in
Tagged knock-in of endogenous geranylgeranylated proteins enables imaging and biochemical tracking of the modified protein in its native context. Knock-in of reporter or affinity tags can also facilitate proteomic identification of prenylated targets.
Overexpression
Overexpression of prenyltransferases or substrate small GTPases can test whether increased geranylgeranylation is sufficient to drive signaling or phenotypic changes. Overexpression models are also useful for testing inhibitor efficacy.
How EDITGENE Supports protein geranylgeranylation Research
Researchers studying protein geranylgeranylation-related genes often need to determine whether a candidate gene is causally involved in membrane targeting, immune cell egress, metabolic balance or disease progression. Establishing causality requires precise genetic models that isolate the geranylgeranylation event from other functions of the same protein.
Contact EDITGENE today to design your custom CRISPR model for protein geranylgeranylation research.
Frequently Asked Questions About protein geranylgeranylation
What is protein geranylgeranylation?
Protein geranylgeranylation (GO:0018344) is the covalent attachment of a geranylgeranyl group to a protein, typically on a C-terminal cysteine, which promotes membrane association and function.
What genes are involved in protein geranylgeranylation?
Key genes include FNTA, FNTB, RABGGTA, RABGGTB, PGGT1B, HMGCR, GGPS1 and FDPS, as well as substrate small GTPases such as RHOA, RAC1, CDC42 and RAB proteins.
What is the difference between farnesylation and geranylgeranylation?
Both are prenylation reactions, but farnesylation adds a 15-carbon group while geranylgeranylation adds a 20-carbon geranylgeranyl group; the balance between them is functionally important.
Which enzymes catalyze protein geranylgeranylation?
Geranylgeranyltransferase I (GGTase-I) and Rab geranylgeranyltransferase (GGTase-II) are the main enzymes, with farnesyltransferase also able to geranylgeranylate some substrates.
How is protein geranylgeranylation regulated?
It is regulated by mevalonate pathway flux, GGPP availability, prenyltransferase expression and metabolic cues, and is sensitive to statins and prenyltransferase inhibitors.
What diseases are linked to protein geranylgeranylation?
Altered geranylgeranylation has been linked to nonalcoholic fatty liver disease, congenital heart defects, immune cell trafficking defects and cancer-related signaling.
Why do statins affect protein geranylgeranylation?
Statins inhibit HMGCR and reduce mevalonate pathway intermediates, including GGPP, thereby indirectly lowering geranylgeranylation of target proteins.
How can I study protein geranylgeranylation in the lab?
Common methods include in vitro prenylation assays, mass spectrometry proteomics, fluorescence imaging of membrane localization, and CRISPR knockout or point-mutation models.
What is the role of geranylgeranylation in immune cells?
Mevalonate metabolism-dependent geranylgeranylation regulates thymocyte egress, and prenylation changes in Th1 cells have been linked to statin and farnesyltransferase inhibitor effects.
Can CRISPR be used to block geranylgeranylation of a specific protein?
Yes, point-mutation knock-in of the CaaX cysteine or knockout of the relevant prenyltransferase can selectively prevent geranylgeranylation of a target protein.
Conclusion
Protein geranylgeranylation (GO:0018344) is a central lipid modification that controls membrane targeting and function of small GTPases and other regulatory proteins. Its dependence on the mevalonate pathway places it at the crossroads of metabolism, immunity and cardiovascular biology, with disease relevance spanning fatty liver disease, congenital heart defects and cancer. Continued research using precise CRISPR models and proteomic methods will clarify how the balance between farnesylation and geranylgeranylation is maintained and how it can be therapeutically modulated.
References
- 1. Zhao Y et al.. 2020. The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.. J Biol Chem 295(15):5152-5162 PMID: 32139507
- 2. Xu N et al.. 2015. Protein prenylation and human diseases: a balance of protein farnesylation and geranylgeranylation.. Sci China Life Sci 58(4):328-35 PMID: 25862656
- 3. Du X et al.. 2020. Mevalonate metabolism-dependent protein geranylgeranylation regulates thymocyte egress.. J Exp Med 217(2) PMID: 31722972
- 4. Ashok S et al.. 2020. Protein Farnesyltransferase Catalyzes Unanticipated Farnesylation and Geranylgeranylation of Shortened Target Sequences.. Biochemistry 59(11):1149-1162 PMID: 32125828
- 5. Phillips HM. 2018. Protein geranylgeranylation: a possible new player in congenital heart defects.. Cardiovasc Res 114(7):922-924 PMID: 29684186
- 6. Watterson A et al.. 2022. Intracellular lipid surveillance by small G protein geranylgeranylation.. Nature 605(7911):736-740 PMID: 35585236
- 7. Koch J et al.. 2025. Uncovering protein prenylation in Th1 cells: novel prenylation sites and insights into statin and farnesyltransferase inhibition.. BMC Biol 23(1):233 PMID: 40745647
- 8. Jung D et al.. 2023. Regulation of protein prenylation.. Biomed Pharmacother 164:114915 PMID: 37236024
